Erythropoietic protoporphyria (EPP) is an inherited disorder caused by a partial deficiency of the enzyme ferrochelatase. Ferrochelatase catalyzes the insertion of ferrous ions into protoporphyrin IX, the last step in heme biosynthesis. As a result of ferrochelatase deficiency, protoporphyrin is accumulated in various tissues; this accumulation is responsible for the clinical symptoms of light sensitivity and, in rare cases, liver damage (1 ). Several mutations have been identified in the human ferrochelatase (FECH) gene among EPP patients (2 ). The results indicate a possible link between the "null-allele" mutations (i.e., mutations that lead to the formation of a truncated enzyme) in the FECH gene and liver complications in EPP (3 ). Although EPP is considered an autosomal dominant disorder, only ϳ10% of individuals with a defective enzyme develop clinical symptoms. A recent study suggested that symptomatic patients differ from asymptomatic gene carriers by the amount of mRNA output from the nonmutated allele. This so-called "low expressed" wild-type FECH allele, identified in EPP patients, is highly associated with a specific haplotype at two single nucleotide polymorphism (SNP) sites in the FECH gene namely, a G at the Ϫ251 position in the promoter region and a T at IVS1-23 (4 ). These latest developments in the pathogenesis of EPP allow prediction of the clinical course of the disease. We report here the first study conducted in an EPP family from Poland.
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The proband was a 15-year-old female patient from Masuria in the northern part of Poland who had been suffering from photosensitivity since early childhood. The diagnosis of EPP was established based on the clinical symptom and laboratory analyses ( Table 1) . Ferrochelatase activity in the proband was reduced to 25% of the mean value, as is typical for EPP patients (5 ) . A massive increase of protoporphyrin concentration was measured in both the red cells and feces. The patient had normal liver function. Although asymptomatic, the proband's father exhibited a Ͼ50% reduction in ferrochelatase activity accompanied by a moderate increase of protoporphyrin concentration in the red cells. Neither clinical nor laboratory abnormalities were observed in the other two members of the family.
Peripheral blood samples were collected from all members of the family for isolation of genomic DNA. All 11 coding exons as well as the flanking intronic regions of the FECH gene were analyzed in the genomic DNA from the proband by denaturing gradient gel electrophoresis (DGGE) according to a method described previously (2 ) . An abnormal DGGE pattern was observed in exon 5 of the FECH gene (Fig. 1A) . Direct sequencing of the PCRamplified fragment containing exon 5 revealed a missense mutation, T545G, which led to the conversion of Leu-182 to Arg in ferrochelatase.
Because T545G (L182R) was, to our knowledge, a novel missense mutation in the FECH gene, its effect on enzyme activity was examined in vitro. The L182R mutation was introduced into a wild-type FECH cDNA cloned into prokaryotic expression vector pGEX-2 (2 ). Ferrochelatase activity of the mutant in the crude bacterial cell extracts was 0.17 Ϯ 0.02 U (an average of four independent clones), which corresponds to Ͻ6% of the activity of 2.85 Ϯ 0.5 U observed with the wild-type FECH cDNA. This result demonstrated that L182R was indeed a causative missense mutation. Because no other sequence abnormalities were found in the FECH gene, L182R was likely the cause of the EPP condition in the patient. Because the patient is a carrier of a missense mutation rather than a null-allele mutation, she is highly unlikely to develop EPP-related liver complications later in life, based on current knowledge (3 ). The other three members of the family were screened specifically for the L182R mutation by DGGE. As shown in Fig. 1A , T5453 G (L182R) was also present in the DNA sample from proband's father but was absent in samples from both her mother and her brother. The molecular analysis confirmed that the proband's father was an asymptomatic carrier of mutation L182R.
As discussed earlier, two SNPs in the ferrochelatase gene, namely, Ϫ251A/G in the promoter region and Ϫ23C/T in intron 1, play a role in the pathogenesis of EPP (4 ) . To verify the latest findings, the two SNPs were studied in all four members of the family, using the method described by Gouya et al. (4 ) . Both the proband and her mother were heterozygous for both SNPs, whereas the proband's father and brother were homozygous (Ϫ251A; IVS1-23C; Fig. 1B ). Mutation L182R resided in one of the (Ϫ251A; IVS1-23C) alleles in the father, which was passed to his daughter, the proband. From her mother, the proband inherited a wild-type FECH allele featuring the haplotype (Ϫ251G; IVS1-23T). According to the study of Gouya et al. (4 ) , the risk for a carrier of a FECH mutation to develop EPP clinically is 60% if the person bears a wild-type FECH allele featuring the haplotype (Ϫ251G; IVS1-23T), which was the case in the proband. At the age of 40, the proband's father was asymptomatic, and he is likely to remain so throughout his life: the likelihood that he will develop clinical symptoms is Ͻ2% because he carries a wild-type FECH allele featuring the haplotype (Ϫ251A; IVS1-23C). Our study has shown that molecular analysis of the FECH gene is able not only to detect the genetic defects underlining the EPP condition among patients and thereby enables an accurate diagnosis of asymptomatic gene carriers, but also is able to provide important clues on the clinical prognosis of the affected individuals. This work was supported by the Swiss National Science Foundation (Grant 31-53799.98). Dried blood on filter paper has been found to be suitable in large-scale population screening programs (1-3 ) , but to the best of our knowledge, dried blood or serum on filter paper has not been used for lipid measurements. In the present study, we evaluated the stability of cholesterol and triglycerides in serum dried on filter paper.
Measurement of Cholesterol and Triglycerides in Dried
Fifty-four patients coming to the centralized laboratory, CNC, All India Institute of Medical Sciences for lipid investigations were selected at random, and blood was collected by venipuncture into tubes without anticoagulant. Serum was separated within 2 h of collection. All 
